Raymond James & Associates Cyma Bay Therapeutics, Inc. Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 16, 2024	BUY	$12.63 - $24.47 $224,447 - $434,856	17,771 Added 44.97%	57,286 $1.35 Million
Q3 2023 Oct 24, 2023	BUY	$10.86 - $17.62 $54,843 - $88,981	5,050 Added 14.65%	39,515 $589,000
Q2 2023 Jul 25, 2023	BUY	$7.47 - $10.95 $91,851 - $134,641	12,296 Added 55.46%	34,465 $377,000
Q1 2023 Apr 14, 2023	SELL	$5.88 - $9.59 $38,878 - $63,409	-6,612 Reduced 22.97%	22,169 $193,000
Q4 2022 Feb 08, 2023	SELL	$3.22 - $6.27 $75,360 - $146,743	-23,404 Reduced 44.85%	28,781 $180,000
Q3 2022 Oct 25, 2022	SELL	$2.77 - $4.25 $101,179 - $155,239	-36,527 Reduced 41.17%	52,185 $183,000
Q2 2022 Aug 12, 2022	SELL	$1.72 - $3.39 $15,294 - $30,143	-8,892 Reduced 9.11%	88,712 $262,000
Q1 2022 May 11, 2022	BUY	$2.77 - $3.64 $56,333 - $74,026	20,337 Added 26.32%	97,604 $304,000
Q4 2021 Feb 08, 2022	SELL	$3.23 - $4.6 $18,704 - $26,638	-5,791 Reduced 6.97%	77,267 $261,000
Q3 2021 Nov 02, 2021	SELL	$3.47 - $4.42 $57,279 - $72,960	-16,507 Reduced 16.58%	83,058 $303,000
Q2 2021 Aug 11, 2021	SELL	$3.94 - $4.92 $8,317 - $10,386	-2,111 Reduced 2.08%	99,565 $434,000
Q1 2021 May 14, 2021	BUY	$4.23 - $6.55 $220,983 - $342,185	52,242 Added 105.68%	101,676 $462,000
Q4 2020 Feb 12, 2021	BUY	$5.73 - $9.03 $123,063 - $193,937	21,477 Added 76.82%	49,434 $284,000
Q3 2020 Nov 04, 2020	BUY	$3.32 - $7.24 $92,817 - $202,408	27,957 New	27,957 $202,000
Q1 2020 Apr 21, 2020	SELL	$1.25 - $2.02 $13,823 - $22,339	-11,059 Closed	0 $0
Q4 2019 Feb 12, 2020	SELL	$1.33 - $5.93 $49,916 - $222,558	-37,531 Reduced 77.24%	11,059 $22,000
Q3 2019 Nov 07, 2019	SELL	$5.12 - $7.21 $29,199 - $41,118	-5,703 Reduced 10.5%	48,590 $249,000
Q2 2019 Aug 06, 2019	BUY	$6.05 - $13.66 $16,819 - $37,974	2,780 Added 5.4%	54,293 $389,000
Q1 2019 May 06, 2019	SELL	$8.16 - $13.42 $250,446 - $411,886	-30,692 Reduced 37.34%	51,513 $684,000
Q4 2018 Feb 11, 2019	BUY	$6.54 - $11.74 $38,579 - $69,254	5,899 Added 7.73%	82,205 $647,000
Q3 2018 Nov 14, 2018	BUY	$10.88 - $14.52 $368,908 - $492,329	33,907 Added 79.97%	76,306 $845,000
Q2 2018 Aug 14, 2018	BUY	$10.66 - $14.38 $1,801 - $2,430	169 Added 0.4%	42,399 $569,000
Q1 2018 May 14, 2018	SELL	$9.0 - $15.16 $98,262 - $165,516	-10,918 Reduced 20.54%	42,230 $549,000
Q4 2017 Feb 14, 2018	BUY	$7.67 - $9.31 $136,894 - $166,164	17,848 Added 50.56%	53,148 $489,000
Q3 2017 Nov 13, 2017	BUY	$5.95 - $8.26 $210,035 - $291,578	35,300	35,300 $285,000

Others Institutions Holding CBAY

# of Institutions

Shares Held

1.82M

Call Options Held

Put Options Held

View Full List

About CymaBay Therapeutics, Inc.

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

More about CBAY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account